14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
XSD vs XPH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, SPDR S&P Pharmaceuticals ETF (XPH) is the stronger overall head-to-head candidate over SPDR S&P Semiconductor ETF (XSD) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). XSD carries a Unified Composite Score of 54.2/100 (HOLD) at $420.62 (N/M Forward P/E, N/A operating margin), whereas XPH carries 41.0/100 (SELL) at $65.55 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While XSD currently prints a higher short-term Unified Composite Score (54.2/100 HOLD vs. XPH 41.0/100 SELL), XPH captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
Technical & Structure Timing Caution: XSD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.2); meanwhile XPH trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XSD vs XPH. Trailing 12-month operating profitability (XSD N/A vs XPH N/A) and valuation multiples (XSD N/M vs XPH N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ XSD vs XPH Key Questions & Quantitative Answers
As of Nov 16, 2026, SPDR S&P Pharmaceuticals ETF (XPH) is the stronger overall head-to-head candidate over SPDR S&P Semiconductor ETF (XSD) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). XSD carries a Unified Composite Score of 54.2/100 (HOLD) at $420.62 (N/M Forward P/E, N/A operating margin), whereas XPH carries 41.0/100 (SELL) at $65.55 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While XSD currently prints a higher short-term Unified Composite Score (54.2/100 HOLD vs. XPH 41.0/100 SELL), XPH captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY). Technical & Structure Timing Caution: XSD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.2); meanwhile XPH trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
XSD and XPH split Growth & Scale metrics: XSD posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with XPH at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, XSD generates N/A in USD-normalized revenue versus N/A for XPH. In operating R&D and SG&A reinvestment, XSD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XPH.
XSD and XPH trade at balanced relative valuation multiples. XSD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas XPH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XSD (N/A ROE) versus XPH (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, XSD carries 33.2% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.77β · 70% Vol realized risk). By comparison, XPH carries 20.9% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 33% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.